The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant potential in clinical trials for treating obesity. Unlike some current weight loss treatments, retatrutide appears to provide a greater substantial reduction in body mass and benefit metabolic markers, p